Who are Oteseconazole (VT-1161)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vivjoa, Cresemba, Jublia, Luzu, POSACONAZOLE, VORICONAZOLE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oteseconazole-vt-1161.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oteseconazole (VT-1161) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oteseconazole (VT-1161) (Oteseconazole (VT-1161)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Azole antifungal. Area: Infectious Disease.

phase 3 Azole antifungal Fungal lanosterol 14α-demethylase (CYP51) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Oteseconazole (VT-1161) (Oteseconazole (VT-1161)) — Mycovia Pharmaceuticals Inc.. Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oteseconazole (VT-1161) TARGET	Oteseconazole (VT-1161)	Mycovia Pharmaceuticals Inc.	phase 3	Azole antifungal	Fungal lanosterol 14α-demethylase (CYP51)
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Jublia	EFINACONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2014-01-01
Luzu	LULICONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2013-01-01
POSACONAZOLE	POSACONAZOLE		marketed	Azole Antifungal [EPC]		2005-01-01
VORICONAZOLE	VORICONAZOLE		marketed	Azole Antifungal [EPC]		2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Azole antifungal class)

Pfizer · 3 drugs in this class
Elion Therapeutics, Inc. · 1 drug in this class
Hadassah Medical Organization · 1 drug in this class
Hatem AbuHashim · 1 drug in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · 1 drug in this class
Military Hospital of Tunis · 1 drug in this class
Mycovia Pharmaceuticals Inc. · 1 drug in this class
Nuvation Bio Inc. · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oteseconazole (VT-1161) — Competitive Intelligence Brief. https://druglandscape.com/ci/oteseconazole-vt-1161. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab